Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Vivi Li -- 6523 2022-12-01 01:44:07

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. BRCA Mutation. Encyclopedia. Available online: https://encyclopedia.pub/entry/37473 (accessed on 25 September 2026).
HandWiki. BRCA Mutation. Encyclopedia. Available at: https://encyclopedia.pub/entry/37473. Accessed September 25, 2026.
HandWiki. "BRCA Mutation" Encyclopedia, https://encyclopedia.pub/entry/37473 (accessed September 25, 2026).
HandWiki. (2022, December 01). BRCA Mutation. In Encyclopedia. https://encyclopedia.pub/entry/37473
HandWiki. "BRCA Mutation." Encyclopedia. Web. 01 December, 2022.
BRCA Mutation
Edit
The content is sourced from: https://handwiki.org/wiki/Medicine:BRCA_mutation

A BRCA mutation is a mutation in either of the BRCA1 and BRCA2 genes, which are tumour suppressor genes. Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, while others have no proven impact. Harmful mutations in these genes may produce a hereditary breast–ovarian cancer syndrome in affected persons. Only 5–10% of breast cancer cases in women are attributed to BRCA1 and BRCA2 mutations (with BRCA1 mutations being slightly more common than BRCA2 mutations), but the impact on women with the gene mutation is more profound. Women with harmful mutations in either BRCA1 or BRCA2 have a risk of breast cancer that is about five times the normal risk, and a risk of ovarian cancer that is about ten to thirty times normal. The risk of breast and ovarian cancer is higher for women with a high-risk BRCA1 mutation than with a BRCA2 mutation. Having a high-risk mutation does not guarantee that the woman will develop any type of cancer, or imply that any cancer that appears was actually caused by the mutation, rather than some other factor. High-risk mutations, which disable an important error-free DNA repair process (homology directed repair), significantly increase the person's risk of developing breast cancer, ovarian cancer and certain other cancers. Why BRCA1 and BRCA2 mutations lead preferentially to cancers of the breast and ovary is not known, but lack of BRCA1 function seems to lead to non-functional X-chromosome inactivation. Not all mutations are high-risk; some appear to be harmless variations. The cancer risk associated with any given mutation varies significantly and depends on the exact type and location of the mutation and possibly other individual factors. Mutations can be inherited from either parent and may be passed on to both sons and daughters. Each child of a genetic carrier, regardless of sex, has a 50% chance of inheriting the mutated gene from the parent who carries the mutation. As a result, half of the people with BRCA gene mutations are male, who would then pass the mutation on to 50% of their offspring, male or female. The risk of BRCA-related breast cancers for men with the mutation is higher than for other men, but still low. However, BRCA mutations can increase the risk of other cancers, such as colon cancer, pancreatic cancer, and prostate cancer. Methods to diagnose the likelihood of a patient with mutations in BRCA1 and BRCA2 getting cancer were covered by patents owned or controlled by Myriad Genetics. Myriad's business model of exclusively offering the diagnostic test led to Myriad growing from being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012; it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.

homology breast cancer ovarian cancer

References

  1. Morris, Joi L.; Gordon, Ora K. (2010). Positive Results: Making the Best Decisions When You're at High Risk for Breast or Ovarian Cancer. Amherst, N.Y.: Prometheus Books. ISBN 978-1-59102-776-8. https://archive.org/details/isbn_9781591027768. 
  2. Chen, S.; Parmigiani, G. (Apr 2007). "Meta-analysis of BRCA1 and BRCA2 penetrance.". J Clin Oncol 25 (11): 1329–1333. doi:10.1200/JCO.2006.09.1066. PMID 17416853.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2267287
  3. "Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer". Journal of the American Medical Association 297 (23): 2587–2595. 2007. doi:10.1001/jama.297.23.2587. PMID 17579227.  https://dx.doi.org/10.1001%2Fjama.297.23.2587
  4. Veronesi, A.; De Giacomi, C. D.; Magri, M. D.; Lombardi, D.; Zanetti, M.; Scuderi, C.; Dolcetti, R.; Viel, A. et al. (2005). "Familial breast cancer: Characteristics and outcome of BRCA 1–2 positive and negative cases". BMC Cancer 5: 70. doi:10.1186/1471-2407-5-70. PMID 15996267.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1184063
  5. Budroni, M.; Cesaraccio, R.; Coviello, V.; Sechi, O.; Pirino, D.; Cossu, A.; Tanda, F.; Pisano, M. et al. (2009). "Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia". BMC Cancer 9: 62. doi:10.1186/1471-2407-9-62. PMID 19232099.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2653541
  6. Verhoog, L. C.; Brekelmans, C. T.; Seynaeve, C.; Van Den Bosch, L. M.; Dahmen, G.; Van Geel, A. N.; Tilanus-Linthorst, M. M.; Bartels, C. C. et al. (1998). "Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1". Lancet 351 (9099): 316–321. doi:10.1016/S0140-6736(97)07065-7. PMID 9652611.  https://dx.doi.org/10.1016%2FS0140-6736%2897%2907065-7
  7. Kurian, AW; Sigal, BM; Plevritis, SK (Jan 2010). "Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.". J Clin Oncol 28 (2): 222–231. doi:10.1200/JCO.2009.22.7991. PMID 19996031.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2815712
  8. Friedenson B (2005). "BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian". MedGenMed 7 (2): 60. PMID 16369438.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1681605
  9. Friedenson B (2007). "The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers". BMC Cancer 7: 15. doi:10.1186/1471-2407-7-152. PMID 17683622.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1959234
  10. Fishman A (October 2010). "The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review". Int. J. Gynecol. Cancer 20 (11 Suppl 2): S31–S33. doi:10.1111/IGC.0b013e3181f60d4d. PMID 20975359.  https://dx.doi.org/10.1111%2FIGC.0b013e3181f60d4d
  11. "Fertility in women with BRCA mutations: a case-control study". Fertil. Steril. 93 (6): 1805–1808. April 2010. doi:10.1016/j.fertnstert.2008.12.052. PMID 19200971.  https://dx.doi.org/10.1016%2Fj.fertnstert.2008.12.052
  12. Broer, S. L.; Broekmans, F. J. M.; Laven, J. S. E.; Fauser, B. C. J. M. (2014). "Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications". Human Reproduction Update 20 (5): 688–701. doi:10.1093/humupd/dmu020. ISSN 1355-4786. PMID 24821925.  https://dx.doi.org/10.1093%2Fhumupd%2Fdmu020
  13. Oktay, K; Kim, JY; Barad, D; Babayev, SN (Jan 2010). "Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.". J Clin Oncol 28 (2): 240–244. doi:10.1200/JCO.2009.24.2057. PMID 19996028.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3040011
  14. Moslehi, R; Singh, R; Lessner, L; Friedman, JM (March–April 2010). "Impact of BRCA mutations on female fertility and offspring sex ratio.". Am J Hum Biol 22 (2): 201–205. doi:10.1002/ajhb.20978. PMID 19642207.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3739697
  15. Balmaña, Judith; Díez, Orland; Campos, Berta; Majewski, Magdalena; Sanz, Judit; Alonso, Carmen; Baiget, Montserrat; Garber, Judy E. (August 2005). "Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?". Breast Cancer Research and Treatment 92 (3): 273–277. doi:10.1007/s10549-005-3377-x. ISSN 0167-6806. PMID 16155798.  https://dx.doi.org/10.1007%2Fs10549-005-3377-x
  16. Agnese, D M (March 2006). "Battle of the BRCA1/BRCA2 (offspring) sex ratios: truth or consequences". Journal of Medical Genetics 43 (3): 201–202. doi:10.1136/jmg.2004.028977. ISSN 0022-2593. PMID 16033919.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2563236
  17. "Breastfeeding and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers". Breast Cancer Res 14 (2): R42. 2012. doi:10.1186/bcr3138. PMID 22405187.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3446376
  18. Yoshida K, Miki Y; Miki (November 2004). "Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage". Cancer Science 95 (11): 866–871. doi:10.1111/j.1349-7006.2004.tb02195.x. PMID 15546503.  https://dx.doi.org/10.1111%2Fj.1349-7006.2004.tb02195.x
  19. Cui, J; Antoniou, AC; Dite, GS; Southey, MC; Venter, DJ; Easton, DF; Giles, GG; McCredie, MR et al. (Feb 2001). "After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer". Am J Hum Genet 68 (2): 420–431. doi:10.1086/318187. PMID 11133358.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1235275
  20. Greenberg RA (September 2006). "BRCA mutations and childhood cancer". Cancer Biol. Ther. 5 (9): 1103–1104. doi:10.4161/cbt.5.9.3370. PMID 17012842.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2703724
  21. US Preventive Services Task, Force.; Owens, DK; Davidson, KW; Krist, AH; Barry, MJ; Cabana, M; Caughey, AB; Doubeni, CA et al. (20 August 2019). "Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.". JAMA 322 (7): 652–665. doi:10.1001/jama.2019.10987. PMID 31429903.  https://dx.doi.org/10.1001%2Fjama.2019.10987
  22. Pagon, RA.; Adam, MP.; Ardinger, HH.; Bird, TD.; Dolan, CR.; Fong, CT.; Smith, RJH.; Stephens, K. et al. (1993). BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. 381–385. doi:10.1016/b0-12-227555-1/00090-3. ISBN 9780122275555.  https://dx.doi.org/10.1016%2Fb0-12-227555-1%2F00090-3
  23. Rosenberg, Shoshana M.; Ruddy, Kathryn J.; Tamimi, Rulla M.; Gelber, Shari; Schapira, Lidia; Come, Steven; Borges, Virginia F.; Larsen, Bryce et al. (2016-02-11). "BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer". JAMA Oncology 2 (6): 730–736. doi:10.1001/jamaoncol.2015.5941. ISSN 2374-2445. PMID 26867710.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5002892
  24. "Referral guidelines - cancer genetics". http://www.gosh.nhs.uk/health-professionals/clinical-specialties/clinical-genetics-information-health-professionals/refer-patient-genetics-department/referral-guidelines-cancer-genetics. 
  25. Pijpe, A.; Andrieu, N.; Easton, D. F.; Kesminiene, A.; Cardis, E.; Noguès, C.; Gauthier-Villars, M.; Lasset, C. et al. (2012). "Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: Retrospective cohort study (GENE-RAD-RISK)". BMJ 345: e5660. doi:10.1136/bmj.e5660. PMID 22956590.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3435441
  26. Lynch, H. T.; Casey, M. J.; Snyder, C. L.; Bewtra, C.; Lynch, J. F.; Butts, M.; Godwin, A. K. (2009). "Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management". Molecular Oncology 3 (2): 97–137. doi:10.1016/j.molonc.2009.02.004. PMID 19383374.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2778287
  27. Moorman, P. G.; Havrilesky, L. J.; Gierisch, J. M.; Coeytaux, R. R.; Lowery, W. J.; Peragallo Urrutia, R.; Dinan, M.; McBroom, A. J. et al. (2013). "Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis". Journal of Clinical Oncology 31 (33): 4188–4198. doi:10.1200/JCO.2013.48.9021. PMID 24145348.  https://dx.doi.org/10.1200%2FJCO.2013.48.9021
  28. Iodice, Simona; Barile, Monica; Rotmensz, Nicole; Feroce, Irene; Bonanni, Bernardo; Radice, Paolo; Bernard, Loris; Maisonneuve, Patrick et al. (August 2010). "Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis". European Journal of Cancer 46 (12): 2275–2284. doi:10.1016/j.ejca.2010.04.018. PMID 20537530. https://www.researchgate.net/publication/44663020. Lu, Karen H.; Berchuck, Andrew; Kauff, Noah D. (2013). "Hereditary gynecologic cancers". in Barakat, Richard D.; Berchuck, Andrew; Markman, Maurie et al.. Principles and practice of gynecologic oncology (6th ed.). Philadelphia: Lippincott Williams & Wilkins. ISBN 978-1-4698-3148-0. https://books.google.com/books?id=7QbZCx5d-zoC&pg=PT262. Isaacs, Claudine; Fletcher, Suzanne W.; Peskin, Beth N. (May 2013). "Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations". in Hayes, Daniel F.; Duda, Rosemary B.. Waltham, Mass.: UpToDate. http://www.uptodate.com/contents/management-of-hereditary-breast-and-ovarian-cancer-syndrome-and-patients-with-brca-mutations. PDQ Cancer Genetics Editorial Board (7 June 2013). "PDQ Genetics of breast and ovarian cancer (Health professional version)". Bethesda, Md.: National Cancer Institute. http://cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page1/AllPages. 
  29. Cibula, David; Zikan, Michal; Dusek, Ladislav; Majek, Ondrej (August 2011). "Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis". Expert Review of Anticancer Therapy 11 (8): 1197–1207. doi:10.1586/era.11.38. PMID 21916573.  https://dx.doi.org/10.1586%2Fera.11.38
  30. Pruthi, S.; Gostout, B. S.; Lindor, N. M. (2010). "Identification and Management of Women with BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer". Mayo Clinic Proceedings 85 (12): 1111–1120. doi:10.4065/mcp.2010.0414. PMID 21123638.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2996153
  31. Burke, Wylie (1997-03-26). "Recommendations for follow-up care of individuals with an inherited predisposition to cancer: Ii. brca1 and brca2". JAMA 277 (12): 997–1003. doi:10.1001/jama.1997.03540360065034. ISSN 0098-7484. PMID 9091675.  https://dx.doi.org/10.1001%2Fjama.1997.03540360065034
  32. Kwon, J. S.; Tinker, A.; Pansegrau, G.; McAlpine, J.; Housty, M.; McCullum, M.; Gilks, C. B. (2013). "Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers". Obstetrics and Gynecology 121 (1): 14–24. doi:10.1097/AOG.0b013e3182783c2f. PMID 23232752.  https://dx.doi.org/10.1097%2FAOG.0b013e3182783c2f
  33. Stadler, ZK.; Kauff, ND. (Jan 2010). "Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations.". J Clin Oncol 28 (2): 189–191. doi:10.1200/JCO.2009.25.6875. PMID 19996025.  https://dx.doi.org/10.1200%2FJCO.2009.25.6875
  34. Jeffers, Lisa; Reid, Joanne; Fitzsimons, Donna; Morrison, Patrick J; Dempster, Martin (2019-10-09). "Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery". Cochrane Database of Systematic Reviews 2019 (10): CD012894. doi:10.1002/14651858.cd012894.pub2. ISSN 1465-1858. PMID 31595976.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6784162
  35. King, MC; Marks, JH; Mandell, JB (Oct 2003). "Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.". Science 302 (5645): 643–646. doi:10.1126/science.1088759. PMID 14576434. Bibcode: 2003Sci...302..643K.  https://dx.doi.org/10.1126%2Fscience.1088759
  36. Cochran, G.; Hardy, J.; Harpending, H. (2006). "Natural history of Ashkenazi intelligence". Journal of Biosocial Science 38 (5): 659–693. doi:10.1017/S0021932005027069. PMID 16867211.  https://dx.doi.org/10.1017%2FS0021932005027069
  37. "Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study". Nat. Genet. 25 (4): 410–413. 2000. doi:10.1038/78092. PMID 10932184.  https://dx.doi.org/10.1038%2F78092
  38. US5747282 http://www.google.com/patents/US5747282
  39. US5837492 http://www.google.com/patents/US5837492
  40. Schwartz J (2009-05-12). "Cancer Patients Challenge the Patenting of a Gene". The New York Times. https://www.nytimes.com/2009/05/13/health/13patent.html. 
  41. Myriad Investor Page—see "Myriad at a glance" accessed October 2012 http://investor.myriad.com/index.cfm
  42. "ACLU sues over patents on breast cancer genes". CNN. http://edition.cnn.com/2009/HEALTH/05/12/us.genes.lawsuit/index.html. 
  43. Robert Cook-Deegan MD (2010). "Impact of Gene Patents and Licensing Practices on Access to Genetic Testing for Inherited Susceptibility to Cancer: Comparing Breast and Ovarian Cancers to Colon Cancers: Patents and Licensing for Breast, Ovarian and Colon Cancer Testing". Genet. Med. 12 (4 Suppl): S15–S38. doi:10.1097/GIM.0b013e3181d5a67b. PMID 20393305.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3047448
  44. Benowitz S (January 2003). "European groups oppose Myriad's latest patent on BRCA1". J. Natl. Cancer Inst. 95 (1): 8–9. doi:10.1093/jnci/95.1.8. PMID 12509391.  https://dx.doi.org/10.1093%2Fjnci%2F95.1.8
  45. "How Will Myriad Respond to the Next Generation of BRCA Testing?". Robinson, Bradshaw, and Hinson. 2011-03-01. http://www.genomicslawreport.com/index.php/2011/03/01/how-will-myriad-respond-to-the-next-generation-of-brca-testing/. 
  46. "Genetics and Patenting". Human Genome Project Information. U.S. Department of Energy Genome Programs. 2010-07-07. http://www.ornl.gov/sci/techresources/Human_Genome/elsi/patents.shtml. 
  47. Liptak, Adam (13 June 2013). "Supreme Court Rules Human Genes May Not Be Patented". The New York Times. https://www.nytimes.com/2013/06/14/us/supreme-court-rules-human-genes-may-not-be-patented.html. 
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 1.8K
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 01 Dec 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback